1.Comparative Study of Postoperative Patient-controlled Intravenous Analgesia with Lornoxicam and Patient-controlled Epidural Analgesia with,Morphine in Patients Undergoing Orthopaedics Surgery
Ruiming DU ; Qinghong CHENG ; Chen WANG
Journal of Chinese Physician 2002;0(S1):-
Objective To compare the analgesic efficacy and side effects of patient-controlled intravenous analgesia (PCIA) with Lornoxicam and patient-controlled epidural analgesia(PCEA) with morphine in patients undergoing Orthopaedics surgery. Methods 100 ASA Ⅰ-Ⅱ Patients scheduled for Orthopaedic surgery were divided randomly into two groups: Lornoxicam PCIA group( n =50) , Lornoxicam 48mg was diluted to 100ml with normal saline (0.9%NS). Morphine PCEA group( n =50), Morphine 9mg + bupivacaine 150mg were diluted to 100ml with normal saline (0.9%NS) .In both groups the patients were received PCA at a rate of 2ml/h with the bolus dose of 0.5ml and lockout interval of 15min. The loading dose was Lornoxicam 8mg plus Ondansetron 4mg in group PCIA and morphine 1mg and Ondansetron 4mg diluted to 10ml with normal saline (0.9%NS) in group PCEA 30 minutes before the end of operation. BP, RR, ECG, SpO_2 were monitored continuously after operation. Efficacy of analgesia was assessed by VAS scores. Side effects such as drowsiness, sweat, nausea, vomiting and skin pruritus were also observed. Results There was no significant difference in the mean VAS score between group PCIA and group PCEA at 4h, 8h, 16h ,20h, 24h, 32h and 48h. after operation. There was no significant difference in side effects between the two groups except the occurrence of sweat, nausea, vomiting and skin pruritus which was lower in group PCIA than in group PCEA ( P
2.The Changes of HIF-1α and VEGF-A in Myocardial Tissue of Rats with Arrhyth-mias
Yuan ZHANG ; Zhipeng CAO ; Ruiming MAO ; Zhongbo DU ; Li MI ; Xinyi LUO ; Meihui TIAN ; Baoli ZHU
Journal of Forensic Medicine 2017;33(3):225-231
Objective T o observe the expression changes of hypoxia inducible factor-1α (H IF-1α) and vascular endothelial grow th factor-A (V E G F-A ) in rats w ith arrhythm ias, and to explore the differences of the expression pattern in the tw o indicators of acute m yocardial ischem ia caused by arrhythm ias and coronary insufficiency. Methods T he arrhythm ia w as induced by C aC l2, and the expression changes of H IF-1α and V E G F-A w ere detected by im m unohistochem istry, W estern blotting and real-tim e PC R w ithin 6 h after the arrhythm ia in rats. Results T he expression of H IF-1α and V E G F-A show ed diffuse in the m yocardial tissue of rats died from arrhythm ias. B oth of them increased in the early arrhythm ia, then decreased. E xtensive m yocardial ischem ia happened at the beginning of arrhythm ia occurrence and its range didn't expand w ith tim e. Conclusion T he expressions of H IF-1α and V E G F-A in m yocardium of the rats w ith arrhythm ia can provide evidence for the differential diagnosis of acute m yocardial is-chem ia caused by fatal arrhythm ia and coronary insufficiency.
3.Study on biological activity of thrombopoietinⅡ in vivo
Liye ZHONG ; Yunxian CHEN ; Xueyun ZHONG ; Tianhao LIU ; Ruiming OU ; Hongyun ZHAO ; Weiwei SU ; Wei LIN ; Xin DU ; Peili XU
Chinese Journal of Pathophysiology 1986;0(04):-
AIM: To investigate the biological activity of thrombopoietin Ⅱ(TPOⅡ) in vivo , which consists of two new kinds of ligand binding with thrombopoietin receptor. METHODS: Purified ligandⅠof TPOⅡ, artificial compound ligandⅡ of TPOⅡand rhTPO were injected into purebred Babl/c mice respectively in 7 days by intraperitoneal injection once for a day. Then the biological activity of TPOⅡ was analyzed by measuring peripheral platelet counts by the end of the seventh day. RESULTS: On the seventh day, the platelet counts of mice treated by ligandⅠof TPOⅡ were higher than that in the negative control group( P 0.05). On the fourteenth day, the platelet counts increased in two all experimental groups of TPOⅡcompared with negative control group( P 0.05). Moreover the platelet counts of mice in two experimental groups of TPOⅡ and the positive group showed increase with experimental days. CONCLUSION: The purified ligandⅠof TPOⅡ had obvious activity in increasing platelet production, which is not different from the effect of rhTPO.
4.Progress on the application of ultrasound in airway management
Qingda WU ; Zhenwei ZHENG ; Bin LIU ; Ruiming DU
The Journal of Clinical Anesthesiology 2023;39(12):1309-1313
Research on application of ultrasound has made continuous progress in airway manage-ment,providing theoretical basis and new ideas for clinical use of ultrasound in airway management,and ex-panding the application range of ultrasound in airway management.Ultrasound can develop real-time imaging and measure almost all the tissue structures of the whole airway,ensuring the accurate locating and measure-ment of airway anatomical structure,which offers objective theoretical support for airway evaluation.Its char-acteristic of real-time imaging also helps to guide endotracheal intubation,determine the position of endotra-cheal tube and laryngeal mask airway,and assess gastric contents.Artificial intelligence improves the accu-racy and efficiency of ultrasonic identification of anatomical structure,which promotes the expanded applica-tion of ultrasound in airway management.This article briefly outlines the recent advance in the application of ultrasound in guiding endotracheal intubation,confirming endotracheal intubation,detecting laryngeal mask airway position,predicting successful tracheal extubation,predicting difficult airway,locating airway ana-tomical structure,and assessing the risk of gastric aspiration,and discusses the application of ultrasound combined with artificial intelligence in airway management.
5.Clinical characteristics of liver damage in 30 patients with severe coronavirus disease 2019 in Sichuan area
Tianlong LI ; Chao DENG ; Qing DU ; Ruiming YUE ; Sen LU ; Hong CHEN ; Yang GUO ; Xiaobo HUANG
Chinese Critical Care Medicine 2020;32(8):928-932
Objective:To describe the characteristics of liver damage in severe coronavirus disease 2019 (COVID-19) patients in Sichuan area and the effect of antiviral drugs on liver function.Methods:The clinical data of severe COVID-19 patients admitted to Chengdu Public Health Clinical Medical Center from January 21 to February 24, 2020 were retrospectively collected, including demographic data, clinical manifestations and liver function changes within 1 week after admission to intensive care unit (ICU). The changes of liver function during the course of disease in severe COVID-19 patients were analyzed and summarized, and group analysis was performed.Results:A total of 30 COVID-19 patients with complete clinical data were enrolled. The incidence of severe COVID-19 in elderly men was higher (60.0%), with median age of 61 (47, 79) years old, and those aged 80 or above accounted for 23.3%. The severe COVID-19 patients mainly presented with respiratory symptoms such as fever (96.7%), cough (80.0%) and dyspnea (66.7%). The alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil) and prothrombin time (PT) of 30 patients were increased to various degrees within 1 week after ICU admission, and albumin (ALB) was decreased. ① The patients were divided into two groups according to whether to take lopinavir/ritonavir (kaletra). It was shown that the incidence of liver dysfunction in patients taking kaletra was significantly higher than those who did not take kaletra (7-day abnormal rate of ALT was 54% vs. 33%, the abnormal rate of AST was 38% vs. 33%, the abnormal rate of TBil was 8% vs. 0%), but there were no statistical differences (all P > 0.05). ② The patients were divided into normal dose group (500 mg, twice a day, n = 19) and reduced dose group (250 mg, twice a day, n = 5) according to the dosage of kaletra. It was shown that patients taking low-dose kaletra had a smaller effect on liver function within 1 week after ICU admission than those receiving normal dosage, and ALB, TBil in the reduced dose group were significantly lower than those in the normal dose group on the 2nd day after ICU admission [ALB (g/L): 33.3±2.0 vs. 37.5±4.0, TBil (μmol/L): 6.3±3.3 vs. 11.3±4.8, both P < 0.05]. Conclusions:Severe COVID-19 patients in Sichuan area suffered obvious liver damage in the early course of the disease and have a slower recovery. It is important to pay attention to avoid using drugs that can aggravate liver damage while treating the disease. If there is no alternative drug, liver protection treatment should be considered appropriately.
6.Comparson of the immunogenicity of genotypeⅠJapanese encephalitis virus subunit vaccine candidate antigens.
Ruiming YU ; Zhancheng TIAN ; Shandian GAO ; Junzheng DU ; Guangyuan LIU ; Jianxun LUO ; Hong YIN
Chinese Journal of Biotechnology 2020;36(7):1314-1322
To screen the best genotypeⅠJapanese encephalitis virus subunit vaccine candidate antigens, the prMEIII gene, the polytope gene and the prMEIII-polytope fusion gene of the GenotypeⅠJapanese encephalitis virus GS strain were cloned into prokaryotic expression vector pET-30a. The recombinant proteins were obtained after the induction and purification. The prepared recombinant proteins were immunized to mice, and the immunogenicity of the subunit vaccine candidate antigens was evaluated through monitoring the humoral immune response by ELISA, detecting the neutralizing antibody titer by plaque reduction neutralization test, and testing the cell-mediated immune response by lymphocyte proliferation assay and cytokine profiling. The recombinant proteins with the molecular weights of 35 (prMEIII), 28 (polytope antigen) and 57 kDa (prMEIII-polytope) induced strong humoral and cellular immune responses in mice. Compared with prMEIII-polytope and polytope proteins, the prMEIII protein induced a significant expression of IL-2 and IFN-γ (P<0.05) and the significant lymphoproliferation of splenocytes (P<0.05). The neutralizing antibody titer induced by the prMEIII protein was close to that induced by the commercial attenuated vaccine SA14-14-2 (P>0.05). The study suggests that the prMEIII protein can be used for the development of the Japanese encephalitis virus subunit vaccine.
Animals
;
Antibodies, Viral
;
blood
;
Antigens, Viral
;
immunology
;
Encephalitis Virus, Japanese
;
immunology
;
Encephalitis, Japanese
;
immunology
;
prevention & control
;
Immunogenicity, Vaccine
;
Mice
;
Mice, Inbred BALB C
;
Vaccines, Subunit
;
immunology
;
Viral Vaccines
;
immunology
7.Using mouse model to evaluate the immune effect of DNA prime-protein boost strategies targeting Japanese encephalitis virus.
Ruiming YU ; Zhancheng TIAN ; Shandian GAO ; Junzheng DU ; Guiquan GUAN ; Hong YIN
Chinese Journal of Biotechnology 2022;38(8):2902-2911
In order to evaluate the immune effect of the genotype Ⅰ Japanese encephalitis virus prM-E DNA vaccine and the prM-EⅢ fusion protein subunit vaccine on mice using DNA prime-protein boost strategy, the prM-E gene was inserted into the pVAX1 eukaryotic expression vector. The recombinant expression vector prM-E-pVAX1 was constructed as a DNA vaccine for initial immunity, and the recombinant prM-EⅢ fusion protein was obtained using a prokaryotic expression system as a subunit vaccine for enhanced immunity. Thirty two female BALB/c mice aged 4-6 weeks were randomly divided into four groups, and a prM-E-pVAX1 DNA vaccine group, a DNA prime-protein boost immune group, a prM-EⅢ subunit vaccine group, and a pVAX1 vector control group were set up. The specific antibody level in serum was monitored by ELISA, the neutralizing antibody titer was detected by plaque reduction neutralization, and the cellular immune responses induced by different vaccine immune groups were analyzed by cytokine expression abundance and lymphocyte proliferation experiments. The results showed that the neutralizing antibody titers induced by mice immunized with the DNA prime-protein boost strategy were close to that of the group immunized with the single prM-EⅢ subunit vaccine, but significantly higher than that of the group immunized with the single prM-E-pVAX1 DNA vaccine. DNA prime-protein boost strategies induced effective Th1/Th2 immune responses in mouse models, in particular the Th1 cell-mediated immune responses. This study provides a new immune strategy that may facilitate the prevention of Japanese encephalitis.
Animals
;
Antibodies, Neutralizing
;
Antibodies, Viral
;
DNA
;
Disease Models, Animal
;
Encephalitis Virus, Japanese/genetics*
;
Female
;
Mice
;
Mice, Inbred BALB C
;
Vaccines, DNA/genetics*
;
Vaccines, Subunit